BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suzuki K, Endo R, Takikawa Y, Moriyasu F, Aoyagi Y, Moriwaki H, Terai S, Sakaida I, Sakai Y, Nishiguchi S, Ishikawa T, Takagi H, Naganuma A, Genda T, Ichida T, Takaguchi K, Miyazawa K, Okita K. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res. 2018;48:411-423. [PMID: 29235218 DOI: 10.1111/hepr.13045] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kawaratani H, Kondo Y, Tatsumi R, Kawabe N, Tanabe N, Sakamaki A, Okumoto K, Uchida Y, Endo K, Kawaguchi T, Oikawa T, Ishizu Y, Hige S, Takami T, Terai S, Ueno Y, Mochida S, Takikawa Y, Torimura T, Matsuura T, Ishigami M, Koike K, Yoshiji H. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. JCM 2022;11:1571. [DOI: 10.3390/jcm11061571] [Reference Citation Analysis]
2 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Akahane T, Yoshiji H. Role of serum albumin in hepatic encephalopathy. Hepatol Res 2021;51:353-4. [PMID: 33797845 DOI: 10.1111/hepr.13632] [Reference Citation Analysis]
4 Tatsumi R, Suii H, Yamaguchi M, Arakawa T, Nakajima T, Kuwata Y, Toyota J, Hige S. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis. Intern Med 2021;60:1501-7. [PMID: 33361677 DOI: 10.2169/internalmedicine.6039-20] [Reference Citation Analysis]
5 Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541 [PMID: 31293721 DOI: 10.4254/wjh.v11.i6.531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
6 Kawaguchi T, Suzuki F, Imamura M, Murashima N, Yanase M, Mine T, Fujisawa M, Sato I, Yoshiji H, Okita K, Suzuki K. Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials. Hepatol Res 2019;49:404-18. [PMID: 30589492 DOI: 10.1111/hepr.13300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Cheng J, Chen Y, Cao W, Zuo G. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis. Medicine (Baltimore) 2021;100:e28232. [PMID: 34941089 DOI: 10.1097/MD.0000000000028232] [Reference Citation Analysis]
8 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
9 Uchida Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis. Hepatol Res 2020;50:1264-74. [PMID: 32833292 DOI: 10.1111/hepr.13564] [Reference Citation Analysis]
10 Ishikawa T, Endo S, Imai M, Azumi M, Nozawa Y, Sano T, Iwanaga A, Honma T, Yoshida T. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. Intern Med 2020;59:2465-9. [PMID: 33055469 DOI: 10.2169/internalmedicine.5094-20] [Reference Citation Analysis]
11 Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H. Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 2019;49:1406-13. [DOI: 10.1111/hepr.13415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fujiwara Y, Suzuki K, Yusa K, Eizuka M, Miura M, Watanabe Y, Takahashi H, Takikawa Y. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy. Intern Med 2021;60:1027-33. [PMID: 33790139 DOI: 10.2169/internalmedicine.5793-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Kakihara A, Maenohara S, Tokushige K, Ido A. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatol Res 2021;51:445-60. [PMID: 33533150 DOI: 10.1111/hepr.13622] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Okada A, Yamana H, Yamaguchi S, Ikeda Kurakawa K, Matsui H, Fushimi K, Nangaku M, Kadowaki T, Yasunaga H. Outcomes of lactulose plus branched-chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. Hepatol Res 2020;50:693-703. [PMID: 31943593 DOI: 10.1111/hepr.13486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Han X, Luo Z, Wang W, Zheng P, Li T, Mei Z, Wang J. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Front Pharmacol 2021;12:696065. [PMID: 34690751 DOI: 10.3389/fphar.2021.696065] [Reference Citation Analysis]
16 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Sato T, Endo K, Kakisaka K, Suzuki Y, Kooka Y, Sawara K, Ito K, Sasaki M, Takikawa Y. Decreased Mean Kurtosis in the Putamen is a Diagnostic Feature of Minimal Hepatic Encephalopathy in Patients with Cirrhosis. Intern Med 2019;58:1217-24. [PMID: 30626839 DOI: 10.2169/internalmedicine.2116-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Yamana H, Imai S, Yamasaki K, Horiguchi H, Ario K, Komatsu T, Sugimoto R, Katsushima S, Naganuma A, Mano Y, Yamashita T, Kamitsukasa H, Tsuruta S, Jo T, Yasunaga H, Fushimi K, Yatsuhashi H. Prognosis of patients with liver cirrhosis: A multi-center retrospective observational study. Hepatol Res 2021. [PMID: 34492143 DOI: 10.1111/hepr.13711] [Reference Citation Analysis]